Patents by Inventor Stephane Bancel

Stephane Bancel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11377470
    Abstract: Disclosed herein are methods for purifying RNA comprising poly A. Also disclosed herein are compositions such as surfaces and oligonucleotides for purifying RNA comprising polyA. Other embodiments are also disclosed. Commercially-available resins having polythymidine oligonucleotide ligands typically contain less than 30 thymidine (2?deoxy) residues and some commercial resin suppliers utilize a distribution of dT chain lengths, not of a discreet length.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 5, 2022
    Assignee: ModernaTX, Inc.
    Inventors: William Joseph Issa, John Grant Aunins, Stephane Bancel
  • Publication number: 20210299278
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: September 14, 2020
    Publication date: September 30, 2021
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • Publication number: 20210230578
    Abstract: The present invention describes methods of removing DNA from an RNA transcript during the mRNA production process. The method embodies procedures for obtaining an in vitro transcription product, and removing any DNA from the product. The DNA can be removed by adding either free DNase or a resin containing immobilized DNase to the product, and recovering the RNA transcript. Alternatively, the DNA template used in the in vitro transcription reaction is labeled. After transcription, the product is applied to a resin that is configured to bind the label, and the RNA transcript is recovered. To detect whether any residual impurities are left in the RNA transcript product, the product is subjected to nuclease digestion and subsequently to liquid chromatography-tandem mass spectrometry analysis to quantitate any residual DNA. The present invention demonstrates efficient and effective methods of isolating an RNA transcript from an in vitro transcription product.
    Type: Application
    Filed: December 7, 2020
    Publication date: July 29, 2021
    Inventors: William Joseph ISSA, Yuxun WANG, Stephane BANCEL
  • Publication number: 20210115101
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 22, 2021
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • Patent number: 10925935
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: February 23, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Tirtha Chakraborty, Stephane Bancel, Stephen G. Hoge, Atanu Roy, Antonin De Fougerolles, Noubar B. Afeyan
  • Patent number: 10858647
    Abstract: The present invention describes methods of removing DNA from an RNA transcript during the mRNA production process. The method embodies procedures for obtaining an in vitro transcription product, and removing any DNA from the product. The DNA can be removed by adding either free DNase or a resin containing immobilized DNase to the product, and recovering the RNA transcript. Alternatively, the DNA template used in the in vitro transcription reaction is labeled. After transcription, the product is applied to a resin that is configured to bind the label, and the RNA transcript is recovered. To detect whether any residual impurities are left in the RNA transcript product, the product is subjected to nuclease digestion and subsequently to liquid chromatography-tandem mass spectrometry analysis to quantitate any residual DNA. The present invention demonstrates efficient and effective methods of isolating an RNA transcript from an in vitro transcription product.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: December 8, 2020
    Assignee: ModernaTX, Inc.
    Inventors: William Joseph Issa, Yuxun Wang, Stephane Bancel
  • Patent number: 10772975
    Abstract: The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5?-cap, 5?-UTR, a 3?-UTR, and a poly-A region with at least 100 nucleotides.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: September 15, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin De Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Patent number: 10751386
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent microbial infection, or to improve a subject's heath or wellbeing.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: August 25, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Jason P. Schrum, Alexander Aristarkhov
  • Publication number: 20190290742
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Application
    Filed: October 5, 2018
    Publication date: September 26, 2019
    Applicant: ModernaTX, Inc.
    Inventors: Tirtha CHAKRABORTY, Stephane BANCEL, Stephen G. HOGE, Atanu ROY, Antonin DE FOUGEROLLES, Noubar B. AFEYAN
  • Publication number: 20190240351
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 8, 2019
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Jeff Lynn ELLSWORTH, Kenechi EJEBE, Justin GUILD, Matthias JOHN, Paul HATALA, Atanu ROY, Jason P. SCHRUM, Susan WHORISKEY, Kristy M. WOOD
  • Publication number: 20190100748
    Abstract: The present invention describes methods of removing DNA from an RNA transcript during the mRNA production process. The method embodies procedures for obtaining an in vitro transcription product, and removing any DNA from the product. The DNA can be removed by adding either free DNase or a resin containing immobilized DNase to the product, and recovering the RNA transcript. Alternatively, the DNA template used in the in vitro transcription reaction is labeled. After transcription, the product is applied to a resin that is configured to bind the label, and the RNA transcript is recovered. To detect whether any residual impurities are left in the RNA transcript product, the product is subjected to nuclease digestion and subsequently to liquid chromatography-tandem mass spectrometry analysis to quantitate any residual DNA. The present invention demonstrates efficient and effective methods of isolating an RNA transcript from an in vitro transcription product.
    Type: Application
    Filed: July 30, 2018
    Publication date: April 4, 2019
    Inventors: William Joseph ISSA, Yuxun WANG, Stephane BANCEL
  • Publication number: 20190085368
    Abstract: Described are methods for production of RNA transcripts using a non-amplified, linearized DNA tempate in an in vitro transcription reaction. Enzymatic 5? capping and oligo dT purification can also be included in the methods.
    Type: Application
    Filed: September 27, 2018
    Publication date: March 21, 2019
    Inventors: Stephane BANCEL, William Joseph ISSA, John Grant AUNINS, Tirtha CHAKRABORTY
  • Publication number: 20190030129
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.
    Type: Application
    Filed: March 7, 2018
    Publication date: January 31, 2019
    Inventors: Jason P. SCHRUM, Stephane BANCEL, Noubar B. AFEYAN, Kenechi EJEBE
  • Publication number: 20180360995
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of cosmetic polynucleotides, cosmetic primary transcripts and cosmetic mmRNA molecules.
    Type: Application
    Filed: December 18, 2017
    Publication date: December 20, 2018
    Inventors: Stephane BANCEL, Eric Yi-Chun HUANG
  • Patent number: 10155029
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 18, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Tirtha Chakraborty, Stephane Bancel, Stephen G. Hoge, Atanu Roy, Antonin De Fougerolles, Noubar B. Afeyan
  • Patent number: 10138507
    Abstract: Described are methods for production of RNA transcripts using a non-amplified, linearized DNA template in an in vitro transcription reaction. Enzymatic 5? capping and oligo dT purification can also be included in the methods.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 27, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, William Joseph Issa, John Grant Aunins, Tirtha Chakraborty
  • Publication number: 20180318446
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of viruses. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent viral infection, or to improve a subject's heath or wellbeing.
    Type: Application
    Filed: February 26, 2018
    Publication date: November 8, 2018
    Applicant: ModernaTX, Inc.
    Inventors: Stephane Bancel, Jason P. Schrum, Alexander Aristarkhov
  • Publication number: 20180311381
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: October 23, 2017
    Publication date: November 1, 2018
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • Publication number: 20180291335
    Abstract: The present invention relates to compositions, methods and kits using cell phenotype altering polynucleotides, cell phenotype altering primary transcripts and cell phenotype altering mmRNA molecules.
    Type: Application
    Filed: November 16, 2017
    Publication date: October 11, 2018
    Inventors: Stephane Bancel, Antonin de Fougerolles, Susan Whoriskey, Tirtha Chakraborty, Eric Yi-Chun Huang
  • Publication number: 20180271938
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent microbial infection, or to improve a subject's heath or wellbeing.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 27, 2018
    Applicant: ModernaTX, Inc.
    Inventors: Stephane Bancel, Jason P. Schrum, Alexander Aristarkhov